Is CJC-1295 safe to take daily?

CJC-1295 is rated "Generally Safe" based on clinical evidence. Always consult your healthcare provider before starting any supplement.

LOADINGLoading your Pro surface...

Ingredient Research

Graded against 173,636 supplements + 177 published clinical interactions, sourced from PubMed, FDA CAERS, openFDA, NIH DSLD

CJC-1295

MODERATE EVIDENCESupplementLast updated

AVELOR SUMMARY

CJC-1295 is an injectable synthetic analog of growth hormone releasing hormone (GHRH 1-29) that binds covalently to circulating albumin, giving it an estimated plasma half-life of 5.8 to 8.1 days. Human trials do exist, but only four of them and only as short pharmacology studies: two randomized, double-blind, placebo-controlled ascending dose trials in healthy adults plus two small mechanistic studies, all of which measured blood markers only, meaning growth hormone, IGF-1, and in one case serum protein spots. There is not a single human trial of fat loss, lean mass, strength, recovery, sleep, injury healing, or any aging outcome, which are the reasons people actually buy it. The muscle and growth data that circulate online come from rats and from GHRH knockout mice. CJC-1295 has never been approved by any regulator for any indication, it is an injectable drug candidate rather than a food component and so is not a lawful dietary supplement ingredient, the review literature places it in an unapproved gray market operating largely outside regulatory oversight, it is a World Anti-Doping Agency Prohibited Substance under section S2, and the peer-reviewed literature describes that supply chain as frequently mislabeled or contaminated. Treat the online claim set as unproven, because it is.

WHAT IT DOES

CJC-1295 is a tetrasubstituted form of human growth hormone releasing factor 1-29, the same 29 amino acid fragment as sermorelin, with four substitutions that resist breakdown by dipeptidyl peptidase-IV and an added maleimidopropionamide group on a C-terminal lysine. After subcutaneous injection that maleimide group forms a covalent bond with the free thiol on Cys34 of circulating serum albumin, which is what the "DAC" or drug affinity complex label refers to. Albumin bound, the peptide has a markedly extended plasma half-life and was still present in rat plasma beyond 72 hours (Jetté 2005). It then acts on GHRH receptors on anterior pituitary somatotrophs, raising growth hormone output.

The important physiological detail from the human work: CJC-1295 does not create bigger growth hormone pulses. Pulse frequency and pulse amplitude stayed the same, and the entire increase came from raising the trough between pulses, which is what drove the rise in IGF-1 (Ionescu 2006). That is a continuous stimulation pattern, not a restoration of youthful pulsatility, which is the opposite of how the compound is usually marketed.

Two different molecules are sold under this name. The one with published human pharmacokinetic and pharmacodynamic data is the albumin-binding DAC version described above. "CJC-1295 without DAC" is modified GRF(1-29) without the albumin anchor, a short-acting molecule the endocrinology review literature describes as a separate agent, and it is not covered by the Teichman or Ionescu human trials (Dominikowski 2026).

Scan a supplement containing CJC-1295

SAFETY PROFILE

No formal drug interaction study of CJC-1295 has ever been published. Every entry below is mechanism-based, derived from what sustained growth hormone and IGF-1 elevation is known to do and from adverse effects reported for this class of peptides in the review literature. Absence of an interaction from this table is not evidence of safety.

Critical Interactions (Do Not Combine Without Medical Supervision)

Moderate Interactions (Monitor Closely)

Theoretical/Low-Risk Interactions

RELATED RESEARCH

Acacia Fiber

AcarboseANIMAL ONLY. In the NIA Interventions Testing Program, a parallel three-site study in genetically he

Activated Charcoal

Agave Inulin

Scan Your CJC-1295 Supplement Browse all ingredients

Independently graded against 173,636 indexed supplements with 177 published clinical interactions, sourced from PubMed, FDA CAERS, openFDA, and NIH DSLD | Last updated:

Not medical advice. Based on published clinical research and systematic reviews.

Discover More

Explore

Browse All 834 Ingredients Browse All 20 Conditions